HDAC9 and non-small cell lung carcinoma: The crucial role of HDAC in NSCLC paclitaxel resistance in our in vitro, in vivo, and clinical tissues studies and limitation of FDA-approved HDAC inhibitors in solid cancer prompted us to develop novel HDAC inhibitors.